CRISPR Enzyme Cas12a2 Developed for Programmable Cancer Therapy

Scientists have harnessed a novel CRISPR‑associated enzyme, Cas12a2, that slices DNA inside cancer cells, triggering self‑destruction. The enzyme can be programmed with a guide RNA to recognize messenger RNA unique to tumor cells, acting as a "molecular switch of death," according to molecular biologist Yang Liu of the University of Utah.

The approach, described in two Nature papers, showed high specificity in cultured human cells and mouse models, shrinking tumors without harming healthy tissue. Akribion Therapeutics, a German biotech firm, is advancing the technology toward a programmable chemotherapy for head‑and‑neck cancers linked to human papillomavirus, with early clinical data targeted for around 2030. Co‑founder and chief R&D officer Paul Scholz highlighted the goal of generating the first clinical trial results.

The discovery builds on a decade of CRISPR research and follows earlier work by biochemist Ryan Jackson and colleagues at Utah State University, who identified the unusual DNA‑fragmenting behavior of Cas12a2. Delivery of the relatively large Cas protein into cells remains a technical hurdle for future therapeutic use.